16:12 EST Cerus (CERS) raises FY25 product revenue view to $202M-$204M from $200M-$203M
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERS:
- CERS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cerus Corporation’s New Study on Trauma Hemorrhage Treatment: A Potential Game Changer?
- Cerus Corporation: Buy Rating Highlighted by Growth Potential and Undervaluation
- Cerus Corporation’s New Study on Pathogen-Reduced RBCs: A Potential Game-Changer for Sickle Cell Disease
- Cerus Corporation’s New Study on INTERCEPT RBCs: Potential Market Impact